CINECA IRIS Institutional Research Information System

OLIVERO, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.431
EU - Europa 2.906
AS - Asia 1.806
SA - Sud America 81
AF - Africa 64
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 8
Totale 9.328
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.314
CN - Cina 837
IT - Italia 606
SE - Svezia 413
DE - Germania 390
IE - Irlanda 363
FR - Francia 240
SG - Singapore 239
UA - Ucraina 175
IN - India 136
GB - Regno Unito 131
FI - Finlandia 129
KR - Corea 128
VN - Vietnam 124
CA - Canada 93
AT - Austria 82
JP - Giappone 69
ID - Indonesia 66
RU - Federazione Russa 64
PL - Polonia 58
ES - Italia 53
BR - Brasile 51
GR - Grecia 46
HK - Hong Kong 38
NL - Olanda 33
TW - Taiwan 33
AU - Australia 31
BE - Belgio 31
TR - Turchia 30
PK - Pakistan 22
CH - Svizzera 18
RO - Romania 17
MX - Messico 16
DK - Danimarca 14
UZ - Uzbekistan 13
CO - Colombia 12
EG - Egitto 11
IR - Iran 9
MN - Mongolia 9
PH - Filippine 9
PT - Portogallo 9
AR - Argentina 8
EU - Europa 8
MY - Malesia 8
CZ - Repubblica Ceca 7
GA - Gabon 7
TH - Thailandia 7
ZA - Sudafrica 7
NO - Norvegia 6
PE - Perù 6
HR - Croazia 5
HU - Ungheria 5
IQ - Iraq 5
SD - Sudan 5
TN - Tunisia 5
YE - Yemen 5
EC - Ecuador 4
NG - Nigeria 4
CM - Camerun 3
DZ - Algeria 3
IL - Israele 3
MU - Mauritius 3
OM - Oman 3
SA - Arabia Saudita 3
BD - Bangladesh 2
BF - Burkina Faso 2
BG - Bulgaria 2
CD - Congo 2
CI - Costa d'Avorio 2
ET - Etiopia 2
GE - Georgia 2
LB - Libano 2
LU - Lussemburgo 2
NP - Nepal 2
PR - Porto Rico 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BJ - Benin 1
CR - Costa Rica 1
CU - Cuba 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GH - Ghana 1
GT - Guatemala 1
HT - Haiti 1
JM - Giamaica 1
MK - Macedonia 1
ML - Mali 1
MW - Malawi 1
NZ - Nuova Zelanda 1
RS - Serbia 1
RW - Ruanda 1
SC - Seychelles 1
UG - Uganda 1
ZM - Zambia 1
Totale 9.328
Salva come PNG Salva come JPEG
Città #
Chandler 663
Beijing 440
Ann Arbor 429
Dublin 362
Fairfield 196
Singapore 184
Ashburn 168
Houston 167
Nyköping 149
Jacksonville 137
Dearborn 132
Wilmington 129
Torino 128
Medford 126
Villeurbanne 126
Redwood City 121
Princeton 112
Woodbridge 112
Vienna 77
Seattle 72
Dong Ket 66
Cambridge 57
Fremont 57
Guangzhou 57
Pisa 50
Warsaw 49
Jakarta 48
Ottawa 46
Turin 43
Boston 40
Shanghai 40
Rome 34
Santa Clara 31
Boardman 28
Nanjing 28
New York 27
Taipei 26
Tokyo 24
Toronto 24
Stockholm 23
Chengdu 22
West Jordan 22
Wuhan 22
Kunming 21
San Diego 20
Milan 19
Brussels 18
Hangzhou 18
Hanoi 18
Paris 18
Delhi 17
Pune 17
Bengaluru 16
Seoul 16
Madrid 15
Washington 15
Duncan 14
Los Angeles 14
Wokingham 14
San Mateo 13
Central District 12
Hefei 12
Athens 11
Falls Church 11
Gurgaon 11
Hyderabad 11
London 11
Norwalk 11
Helsinki 10
Ankara 9
Bucharest 9
Düsseldorf 9
Ho Chi Minh City 9
Munich 9
Bologna 8
Council Bluffs 8
Lahore 8
Verona 8
Atlanta 7
Barcelona 7
Chongqing 7
Hanover 7
Hebei 7
Kumar 7
Libreville 7
Nanchang 7
Napoli 7
Pacifica 7
Phoenix 7
Shenzhen 7
Sydney 7
Tashkent 7
Amsterdam 6
Des Moines 6
Fuzhou 6
Hong Kong 6
Islamabad 6
Jinan 6
Lima 6
Mountain View 6
Totale 5.500
Salva come PNG Salva come JPEG
Nome #
Hepatitis delta virus diagnosis. 726
Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: Correlation with the ARCHITECT quantitative assays. 427
Outcome of chronic delta hepatitis in Italy: a long-term cohort study. 360
Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α 356
Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II 310
Chronic HCV infection and lymphoproliferative disorders: mixed cryoglobulinemia syndrome, MGUS and B-cell non-Hodgkin lymphoma. 268
Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single center retrospective study 164
Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection 150
Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report 134
Multiple courses of G-CSF in patients with decompensated cirrosi: consistent mobilization of immature cells ex pressing hepatocyte markers and exploratory clinical evaluation. 133
Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR 123
Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations 116
Laboratory evidence of Helicobacter species infection in hepatocellular carcinoma 115
Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease 112
IL28Bpolymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients 108
Serum cytokeratin-19 fragments (CYFRA 21-1) for the prediction of overall survival in patients with hepatocellular carcinoma 108
On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases 107
Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma 107
Biomarkers of oncogenesis, adipose tissue dysfunction and systemic inflammation for the detection of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 106
Incidence of type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: Results of a controlled follow-up study. 105
The clinical role of serum epidermal growth factor receptor 3 in hepatitis c virus-infected patients with early hepatocellular carcinoma 104
Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B 101
Absolute quantification of intrahepatic hepatitis B virus covalently-closed-circular DNA by droplet digital PCR technology 99
Serum levels of protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) at baseline predict overall survival in patients with hepatocellular carcinoma (HCC) 99
Inactive hepatitis B virus carriers: a favourable clinical condition 98
Characterization of a novel chemiluminescent enzyme immunoassay for the quantitation of antibodies to hepatitis B core antigen class IgG and correlation with intrahepatic HBV covalently-closed-circular DNA 97
Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in chronic hepatitis D 96
Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology 96
Cytokeratin 18-Aspartate396 apoptotic fragment for fibrosis detection in patients with non-alcoholic fatty liver disease and chronic viral hepatitis 93
Incidence of Type 2 diabetes mellitus and glucose abnormalities in treated patients with chronic hepatitis C infection: results of a controlled follow-up study. 93
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study 90
Role of serum hepatitis B core-related antigen in chronic hepatitis B infection 90
Prevalence of hepatitis C virus/hepatitis G virus co-infection in Turin: updated data ten years later. 89
AGGIORNAMENTI SULLA TERAPIA DELL'EPATITE B E DELTA 88
Increased Pre-Hepatic Insulin Levels Are Directly Related to Nash, Fibrogenesis and Fibrosis in Non Diabetic NAFLD Patients but Not in Type 2 Diabetes 88
Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine 87
Azione antiproliferativa e modificazioni del citoscheletro indotte da azossicianuri in fibroblasti 87
Epatocarcinoma: biomarcatori nella prevenzione, diagnosi e cura 86
Some biological effects of calvatic acid and its analog on isolated hepatocytes. 85
Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen level in the natural history of chronic HBV infection 85
Diagnostic accuracy of soluble sCD163 for the detection of severe fibrosis in patients with Non-Alcoholic Fatty Liver Disease 85
Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in patients with chronic hepatitis D 82
DROPLET DIGITAL PCR APPLICATION FOR HEPATITIS DELTA VIREMIA QUANTIFICATION 82
Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease 80
Effetto antimicrotubulare della geiparvarina, del dietilstilbestrolo e del loro prodotto di coniugazione 77
Microarrays analysis for predicting treatment response in patients with chronic hepatitis C: preliminary data 75
Aldehyde-induced modifications of the microtubular system in 3T3 fibroblasts. 74
HBV: GLI "END-POINTS" DELLA TERAPIA CON I NUCS + UPDATE 2016 SU NUOVE STRATEGIE TERAPEUTICHE DELL'INFEZIONE CRONICA HBV 74
Immunological and virological markers during pegylated interferon therapy in HDV chronic hepatitis: any predictor of response? 74
Gene expression profiles for predicting treatment response in patients with chronic hepatitis C: preliminary analysis 73
Risk of hepatocellular carcinoma development in patients with cirrhosis of viral etiology assessed by protein induced by vitamin k absence or agonist II 73
Application of serum cytokeratin-19 fragments (CYFRA 21-1) in predicting the prognosis of patients with hepatocellular carcinoma 73
Hepatitis B-core related antigen levels during nucleos(t)ide analogues or pegylated-interferon treatment in patients chronically infected with HBV genotype-D 72
Risk of developing hepatocellular carcinoma in patients with cirrhosis of viral etiology evaluated by the combination of alphafetoprotein, protein induced by vitamin K absence or antagonist-II and glypican-3 71
A NOVEL APPROACH FOR HEPATITIS DELTA VIRUS VIREMIA QUANTIFICATION BY DROPLET DIGITAL PCR ASSAY 70
Cytoskeletal modifications induced by 4-hydroxynonenal 69
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 68
Antimicrotubular effect of calvatic acid and of some related compounds 68
Liver transplantation for hepatitis B with delta coinfection: a single center experience 68
Epidemiology and clinical course of hepatitis delta virus infection over 15 years in a liver center in Northern Italy 67
Impact of IL28B genotype on response rates in hepatitis C virus cirrhotic patients treated with new DAA regimens: experience of a single center 66
Chronic hepatitis B treatmen: current perspectives on Telbivudine 65
Quantification of serum HDV RNA by ddPCR 65
Interplay between Oxidative Stress and Metabolic Derangements in Non-Alcoholic Fatty Liver Disease: The Role of Selenoprotein P 65
4-hydroxynonenal interacts with tubulin by reacting with its functional -SH groups. 63
The influence of calvatic acid and some of its analogues on colchicine-binding activity of rat liver tubulin. 62
Non-invasive methods for the assessment of hepatic fibrosis: transient elastography, hyaluronic acid, 13C-aminopyrine breath test and cytokeratin 18 fragment 62
Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience 62
The hepatitis D virus in Italy. A vanishing infection, not yet a vanished disease 61
Clinical Application of Droplet Digital PCR for Hepatitis Delta Virus Quantification 61
CROSS-SECTIONAL AND LONGITUDINAL EVALUATION OF ALPHA-FETOPROTEIN (AFP) AND PROTEIN INDUCED BY VITAMIN K ABSENCE OR ANTAGONIST II (PIVKA-II) IN PATIENTS WITH CIRRHOSIS OF VIRAL ETIOLOGY UNDER SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA (HCC) 59
Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease 59
HNE antiproliferative effect can be related to an interaction with the cytoskeleton 57
Kinetics of HDV-RNA and hepatitis B surface antigen in chronic delta hepatitis under pegylated interferon and/or nucleoside analogs therapy 57
Impact of PNPLA3 rs738409 polymorphism on the development of liver-related events in patients with non-alcoholic fatty liver disease 55
HLA-B, DRB1 alleles in Italian patients with chronic hepatitis C and responsiveness to interferon + ribavirin therapy 53
Modificazioni del citoscheletro indotte dal 4-idrossinonenale 53
Role of hepatitis B core-related antigen and antibodies to hepatitis B core antigen levels in the natural history of chronic HBV infection 53
HEPATITIS B CORE-RELATED ANTIGEN LEVELS DURING NUCLEOS(T)IDE ANALOGUES OR PEGYLATED-INTERFERON TREATMENT IN PATIENTS WITH CHRONIC HBV-GENOTYPE D INFECTION 49
Risk of developing hepatocellular carcinoma (HCC) in patients with cirrhosis of viral etiology evaluated by the association of alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-II (PIVKA-II) and glypican-3 (GPC-3) 49
Interplay between metabolic derangement, biomarkers of collagen remodelling and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease 49
The influence of calvatic acid and some of its analogues on colchicine-binding activity of tubulin from AH-130 Yoshida ascites hepatoma 48
Epatocarcinoma: biomarcatori nella prevenzione, diagnosi e cura 47
Occult hepatitis B virus infection in patients with chronic hepatitis C treated with antiviral therapy. 46
Hepatitis b virus reactivation upon immunosuppression: Is there a role for hepatitis b core-related antigen in patients with immune-escape mutants? a case report 46
Effect of calvatic acid and its analogs on ornithine decarboxylase activity in tumour cells. 45
Interazione fra geiparvarina, dietilstilbestrolo e microtubuli 45
Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study 45
Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8+ T Cells 43
Interplay between metabolic derangement, hepatic fibrogenesis and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease 43
Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease 42
HCV and TTV Co-infection in Turin, Italy. 42
Reply to: “Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition” 42
Phenylazoxycyanide damages microtubular protein more than its reference antibiotic, calvatic acid. 41
Interaction of C-9 aldehydes with microtubular protein in vitro and in cultured cells in the presence of taxol. 41
Insulin secretion is an independent predictor of hepatic ballooning in non-diabetic fatty liver disease. 41
Serum hepatitis B core-related antigen for the prediction of hepatocellular carcinoma development 40
Performance of cytokeratin-18 apoptotic fragment for the identification of hepatic fibrosis and inflammation in patients with chronic viral hepatitis: a meta-analysis 39
Prevalence of hepatitis delta virus (HDV) infection in chronic hepatitis B patients with unusual clinical pictures. 36
Serum glypican-3 for the prediction of survival in patients with hepatocellular carcinoma 34
Totale 9.492
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.913
article - articoli 0
book - libri 0
conference - conferenze 9.119
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.032
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.017 0 0 0 133 67 172 129 81 118 179 74 64
2020/20211.124 89 128 64 59 96 80 117 53 112 87 73 166
2021/20221.634 52 50 67 113 105 90 142 152 92 162 364 245
2022/20231.960 187 171 66 202 172 464 159 121 197 54 118 49
2023/2024986 128 136 82 71 60 110 45 81 6 60 90 117
2024/2025400 68 172 107 53 0 0 0 0 0 0 0 0
Totale 9.696